| BERGER, Eric |
TOTEM-RRMS, NCT03910738: TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis |
|
|
| Recruiting | 2 | 40 | Europe | Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection, Placebo 4 mL Solution for Injection, MRI, Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities, Assessment of disability | University Hospital, Strasbourg, France, Bayer, Fédération Hospitalo-Universitaire NEUROGENYCS, Grünenthal GmbH | Multiple Sclerosis, Relapsing-Remitting | 01/27 | 01/27 | | |
| Completed | N/A | 206 | Europe | questionnaires | Centre Hospitalier Universitaire de Nice | Multiple Sclerosis | 05/23 | 05/23 | | |
| Completed | N/A | 68 | Europe, RoW | Questionnaire | University Hospital, Bordeaux, Biogen | Multiple Sclerosis | 12/23 | 12/23 | | |
NeurofilMS, NCT03981003: Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis |
|
|
| Recruiting | N/A | 1150 | Europe, RoW | Blood sample | Centre Hospitalier Universitaire de Nīmes, Hospices Civils de Lyon | Multiple Sclerosis | 06/28 | 06/28 | | |
| Recruiting | N/A | 1000 | Europe, RoW | No intervention | Hospices Civils de Lyon | Sclerosis, Multiple, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders, Pregnancy Abnormal | 08/36 | 08/36 | | |
| SIMON, Pauline |
CAALL-F01, NCT02716233: A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents |
|
|
| Recruiting | 3 | 1578 | Europe | pegaspargase 1250 IU/m2 x 2, ONCASPAR 1250 IU/m2 x 2, pegaspargase 2500 IU/m2 x 1, ONCASPAR 2500 IU/m2 x 1 | Assistance Publique - Hôpitaux de Paris, Shire | Acute Lymphoblastic Leukemia | 04/26 | 04/26 | | |
| Recruiting | 3 | 6430 | Europe, RoW | Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Besponsa+Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab, Blincyto | Mats Heyman, The Swedish Research Council, The Swedish Childhood Cancer Foundation, Pfizer, Servier, NordForsk, Aamu Pediatric Cancer Foundation, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Clinical Trial Center North (CTC North GmbH & Co. KG), Belgium Health Care Knowledge Centre, Karolinska Institutet, Cancer Research UK, Fundação Rui Osório de Castro, Acreditar - Associação de Pais e Amigos das Crianças com Cancro, Grupo Português De Leucemias Pediátricas, Amgen, Nova Laboratories Limited, Danish Child Cancer Foundation, Danish Cancer Society, The Novo Nordic Foundation, Assistance Publique - Hôpitaux de Paris, Direction Générale de l'Offre de Soins | Leukemia, Acute Lymphoblastic | 06/27 | 06/32 | | |
| VIENOT, Angélique |
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 600 | Europe, US, RoW | SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo | Panbela Therapeutics, Inc. | Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV | 08/26 | 01/27 | | |
SPARTANA, NCT04894370: Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma |
|
|
| Recruiting | 2 | 34 | Europe | Sample collection | Centre Hospitalier Universitaire de Besancon, National Cancer Institute, France, Novartis | Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma | 06/25 | 11/26 | | |
CLavSyn, NCT03117972: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels |
|
|
| Terminated | 2 | 54 | Europe | FOLFOXIRI, Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, FOLFOX, FOLFIRI, Ironotecan, Bevacizumab, LV5FU2, Capecitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 08/24 | 11/24 | | |
ALIX, NCT03974854: Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma |
|
|
| Terminated | 2 | 25 | Europe | XELOXIRI-3, Capecitabine, Oxaliplatine, Irinotecan, Gemcitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Pancreatic Adenocarcinoma | 08/23 | 02/24 | | |
INTERACT-ION, NCT04719988: Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. |
|
|
| Active, not recruiting | 2 | 55 | Europe | Blood sample collection, Biopsy | Centre Hospitalier Universitaire de Besancon, Boehringer Ingelheim | Squamous Cell Carcinoma of the Anus Stage III | 11/24 | 07/26 | | |
CARE, NCT06425133: Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers |
|
|
| Recruiting | 2 | 174 | Europe | Blood sample, Quality of life questionnaires, Biopsy, Regorafenib, Regorafenib + metronomic chemotherapy | Centre Hospitalier Universitaire de Besancon, Groupement Interrégional de Recherche Clinique et d'Innovation | Metastatic Colorectal Cancer | 09/27 | 09/28 | | |
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI |
|
|
| Recruiting | 2 | 120 | Europe | Dostarlimab, Chemotherapy | UNICANCER, National Cancer Institute, France, GlaxoSmithKline | Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma | 10/28 | 09/30 | | |
PREMICES, NCT06646445: Neoadjuvant Pembrolizumab with a Watch-and-wait Strategy for Patients with DMMR/MSI-H Localized Colon Cancer: GERCOR G-109 PRODIGE 84 Phase II Trial |
|
|
| Not yet recruiting | 2 | 64 | Europe | Pembrolizumab 200mg IV q3w day 1 of 21-day cycle, Keytruda, Watch-and-wait approach, Surgery, Adjuvant chemotherapy | GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD | Colon Cancer | 10/27 | 10/29 | | |
| Recruiting | 2 | 30 | Europe | Nivolumab, Ipilimumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol Myers Squibb | Metastatic Colorectal Cancer | 12/24 | 09/27 | | |
FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme |
|
|
| Recruiting | 2 | 400 | Europe | FOLFOX regimen, CAPOX regimen | UNICANCER | Digestive Cancer, Colorectal Cancer | 04/27 | 01/30 | | |
PANORAMA, NCT06397846: Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions. |
|
|
| Recruiting | N/A | 100 | Europe | Biological sample | Centre Hospitalier Universitaire de Besancon | Benign Pancreatic Lesion | 12/26 | 06/27 | | |
NCT04935853: Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study |
|
|
| Recruiting | N/A | 1350 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Biliary Tract Cancer | 06/30 | 06/40 | | |
| Recruiting | N/A | 4050 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Pancreatic Adenocarcinoma | 12/30 | 12/31 | | |
